Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723144 | 0.82 | CYP2C19 (0.43) | CYP2C19HIF1ATAAR1FFAR4MAPT | |
| SCHEMBL187685 | 0.81 | CYP2C19 (0.46) | POLBCYP2C19HIF1ATAAR1SMN1; SMN2 | |
| SCHEMBL16819649 | 0.79 | CYP1A2 (0.37) | POLBCYP2C19HIF1ATAAR1FFAR4 | |
| SCHEMBL5753278 | 0.79 | FFAR4 (0.50) | CYP2C19HIF1ATAAR1FFAR4SMN1; SMN2 | |
| SCHEMBL16819672 | 0.77 | CYP1A2 (0.36) | POLBCYP2C19HIF1ATAAR1FFAR4 | |
| SCHEMBL11546812 | 0.77 | MAPT (0.35) | SMN1; SMN2MAPTKMT2AHDAC3 | |
| SCHEMBL1829559 | 0.77 | MAPT (0.50) | CYP2C19HIF1ATAAR1FFAR4MAPT | |
| SCHEMBL12723130 | 0.77 | ALDH1A1 (0.46) | CYP2C19HIF1ATAAR1FFAR4SMN1; SMN2 | |
| SCHEMBL12886725 | 0.76 | CYP2C19 (0.43) | CYP2C19HIF1ATAAR1FFAR4MAPT | |
| SCHEMBL16819653 | 0.75 | CYP1A2 (0.38) | POLBCYP2C19HIF1ATAAR1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2019-03-28 | — | — | US | disclosed |
| US-9180116-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2015-06-25 | — | — | US | disclosed |
| EP-1225168-B2 | Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension | PFIZER HEALTH AB (SE) | 2015-01-21 | — | — | EP | disclosed |
| EP-1225168-B1 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | PFIZER HEALTH AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-7163959-B2 | Prostagladin derivatives for the treatment of glaucoma or ocular hypertension | PHARMACIA AKTIEBOLAG (US) | 2007-01-16 | — | — | US | disclosed |
| US-20040167190-A1 | Prostagladin derivatives for the treatment of glaucoma or ocular hypertension | PHARMACIA AKTIEBOLAG | 2004-08-26 | — | — | US | disclosed |
| EP-1348437-A2 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | Pharmacia Aktiebolag (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030181493-A1 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | STJERNSCHANTZ JOHAN WILHELM (SE) | 2003-09-25 | — | — | US | disclosed |
| US-20030166729-A1 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | STJERNSCHANTZ JOHAN WILHELM (SE) | 2003-09-04 | — | — | US | disclosed |
| US-5627208-A | VISION DEFECTS | PHARMACIA AKTIEBOLAG (SE) | 1997-05-06 | — | — | US | disclosed |
| US-5578618-A | TREATMENT OF VISION DEFECTS | PHARMACIA AKTIEBOLAG (SE) | 1996-11-26 | — | — | US | disclosed |
| US-5422368-A | With omega chain having a ring as end group, side effect reduction | KABI PHARMACIA AB (SE) | 1995-06-06 | — | — | US | disclosed |
| US-5422369-A | Topical treatment | KABI PHARMACIA AB (SE) | 1995-06-06 | — | — | US | disclosed |
| US-5321128-A | Vision defects | KABI PHARMACIA AB (SE) | 1994-06-14 | — | — | US | disclosed |
| US-5296504-A | Composition for topical treatment including compatible vehicle | KABI PHARMACIA (SE) | 1994-03-22 | — | — | US | disclosed |
| EP-0364417-B1 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | KABI PHARMACIA AB (SE) | 1994-02-09 | — | — | EP | disclosed |
| EP-0569046-A1 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | Pharmacia AB (SE) | 1993-11-10 | — | — | EP | disclosed |
| EP-0364417-A1 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | Pharmacia AB (SE) | 1990-04-18 | — | — | EP | disclosed |
| WO-1990002553-A1 | PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | PHARMACIA AB (SE) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175538-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | POLB 4459/4885CYP2C19 859/4885HIF1A 1593/4885 |
| US-20190092722-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | POLB 4459/4885CYP2C19 859/4885HIF1A 1593/4885 |
| US-20030181493-A1 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | PTGIR, PTGIS, PTGS1 | POLB 794/4885CYP2C19 187/4885HIF1A 1018/4885 |
| US-20040167190-A1 | Prostagladin derivatives for the treatment of glaucoma or ocular hypertension | PTGIR, PTGIS, PTGS1 | POLB 1879/4885CYP2C19 137/4885HIF1A 1550/4885 |
| US-20030166729-A1 | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | PTGIR, PTGIS, PTGS1 | POLB 624/4885CYP2C19 243/4885HIF1A 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.